Boosting BCG with MV A85A: the first candidate subunit vaccine for tuberculosis in clinical trials

There is an urgent need for an improved vaccine against tuberculosis. Heterologous prime-boost immunization regimes induce higher levels of cellular immunity than homologous boosting with the same vaccine. Using BCG as the priming immunization in such a regime allows for the retention of the benefic...

Full description

Saved in:
Bibliographic Details
Published in:Tuberculosis (Edinburgh, Scotland) Scotland), 2005-03, Vol.85 (1-2), p.47-52
Main Authors: McShane, H, Pathan, A A, Sander, C R, Goonetilleke, N P, Fletcher, HA, Hill, AVS
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 52
container_issue 1-2
container_start_page 47
container_title Tuberculosis (Edinburgh, Scotland)
container_volume 85
creator McShane, H
Pathan, A A
Sander, C R
Goonetilleke, N P
Fletcher, HA
Hill, AVS
description There is an urgent need for an improved vaccine against tuberculosis. Heterologous prime-boost immunization regimes induce higher levels of cellular immunity than homologous boosting with the same vaccine. Using BCG as the priming immunization in such a regime allows for the retention of the beneficial protective effects of BCG against disseminated disease in childhood. Recombinant poxviruses are powerful boosting agents, for both CD4+ and CD8+ T cells. Here we review the preclinical data from a BCG prime-recombinant modified vaccinia virus Ankara expressing antigen 85A (MVA85A) boost strategy. MVA85A is now in clinical trials in the UK and Africa and the design of these trials, including the ethical and regulatory issues are discussed.
doi_str_mv 10.1016/j.tube.2004.09.015
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_17351798</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17351798</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_173517983</originalsourceid><addsrcrecordid>eNqNjcFOAjEQQHvQRFR-wNOcvFGnC-vucgOicOFmuJJuKTKkttKZ6u-7Jn6Ap3d4L3lKPRjUBs3z01lL6b2uEGcaO42mvlIjM2uqSdd01Y26ZT7jEGKLI9UvU2Kh-A7L1Rq-SU6w3cGirRdzkJOHI2UWcDYe6GDFA5e-RBL4ss5RHHzK8LvLroTExEARXKBIzgaQTDbwvbo-DvDjP96px9eXt9Vm8pnTpXiW_Qex8yHY6FPhvWmmtWm6dvrv8AfNGk2E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17351798</pqid></control><display><type>article</type><title>Boosting BCG with MV A85A: the first candidate subunit vaccine for tuberculosis in clinical trials</title><source>ScienceDirect Journals</source><creator>McShane, H ; Pathan, A A ; Sander, C R ; Goonetilleke, N P ; Fletcher, HA ; Hill, AVS</creator><creatorcontrib>McShane, H ; Pathan, A A ; Sander, C R ; Goonetilleke, N P ; Fletcher, HA ; Hill, AVS</creatorcontrib><description>There is an urgent need for an improved vaccine against tuberculosis. Heterologous prime-boost immunization regimes induce higher levels of cellular immunity than homologous boosting with the same vaccine. Using BCG as the priming immunization in such a regime allows for the retention of the beneficial protective effects of BCG against disseminated disease in childhood. Recombinant poxviruses are powerful boosting agents, for both CD4+ and CD8+ T cells. Here we review the preclinical data from a BCG prime-recombinant modified vaccinia virus Ankara expressing antigen 85A (MVA85A) boost strategy. MVA85A is now in clinical trials in the UK and Africa and the design of these trials, including the ethical and regulatory issues are discussed.</description><identifier>ISSN: 1472-9792</identifier><identifier>DOI: 10.1016/j.tube.2004.09.015</identifier><language>eng</language><ispartof>Tuberculosis (Edinburgh, Scotland), 2005-03, Vol.85 (1-2), p.47-52</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>McShane, H</creatorcontrib><creatorcontrib>Pathan, A A</creatorcontrib><creatorcontrib>Sander, C R</creatorcontrib><creatorcontrib>Goonetilleke, N P</creatorcontrib><creatorcontrib>Fletcher, HA</creatorcontrib><creatorcontrib>Hill, AVS</creatorcontrib><title>Boosting BCG with MV A85A: the first candidate subunit vaccine for tuberculosis in clinical trials</title><title>Tuberculosis (Edinburgh, Scotland)</title><description>There is an urgent need for an improved vaccine against tuberculosis. Heterologous prime-boost immunization regimes induce higher levels of cellular immunity than homologous boosting with the same vaccine. Using BCG as the priming immunization in such a regime allows for the retention of the beneficial protective effects of BCG against disseminated disease in childhood. Recombinant poxviruses are powerful boosting agents, for both CD4+ and CD8+ T cells. Here we review the preclinical data from a BCG prime-recombinant modified vaccinia virus Ankara expressing antigen 85A (MVA85A) boost strategy. MVA85A is now in clinical trials in the UK and Africa and the design of these trials, including the ethical and regulatory issues are discussed.</description><issn>1472-9792</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNqNjcFOAjEQQHvQRFR-wNOcvFGnC-vucgOicOFmuJJuKTKkttKZ6u-7Jn6Ap3d4L3lKPRjUBs3z01lL6b2uEGcaO42mvlIjM2uqSdd01Y26ZT7jEGKLI9UvU2Kh-A7L1Rq-SU6w3cGirRdzkJOHI2UWcDYe6GDFA5e-RBL4ss5RHHzK8LvLroTExEARXKBIzgaQTDbwvbo-DvDjP96px9eXt9Vm8pnTpXiW_Qex8yHY6FPhvWmmtWm6dvrv8AfNGk2E</recordid><startdate>20050301</startdate><enddate>20050301</enddate><creator>McShane, H</creator><creator>Pathan, A A</creator><creator>Sander, C R</creator><creator>Goonetilleke, N P</creator><creator>Fletcher, HA</creator><creator>Hill, AVS</creator><scope>7QL</scope><scope>C1K</scope></search><sort><creationdate>20050301</creationdate><title>Boosting BCG with MV A85A: the first candidate subunit vaccine for tuberculosis in clinical trials</title><author>McShane, H ; Pathan, A A ; Sander, C R ; Goonetilleke, N P ; Fletcher, HA ; Hill, AVS</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_173517983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McShane, H</creatorcontrib><creatorcontrib>Pathan, A A</creatorcontrib><creatorcontrib>Sander, C R</creatorcontrib><creatorcontrib>Goonetilleke, N P</creatorcontrib><creatorcontrib>Fletcher, HA</creatorcontrib><creatorcontrib>Hill, AVS</creatorcontrib><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Tuberculosis (Edinburgh, Scotland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McShane, H</au><au>Pathan, A A</au><au>Sander, C R</au><au>Goonetilleke, N P</au><au>Fletcher, HA</au><au>Hill, AVS</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Boosting BCG with MV A85A: the first candidate subunit vaccine for tuberculosis in clinical trials</atitle><jtitle>Tuberculosis (Edinburgh, Scotland)</jtitle><date>2005-03-01</date><risdate>2005</risdate><volume>85</volume><issue>1-2</issue><spage>47</spage><epage>52</epage><pages>47-52</pages><issn>1472-9792</issn><abstract>There is an urgent need for an improved vaccine against tuberculosis. Heterologous prime-boost immunization regimes induce higher levels of cellular immunity than homologous boosting with the same vaccine. Using BCG as the priming immunization in such a regime allows for the retention of the beneficial protective effects of BCG against disseminated disease in childhood. Recombinant poxviruses are powerful boosting agents, for both CD4+ and CD8+ T cells. Here we review the preclinical data from a BCG prime-recombinant modified vaccinia virus Ankara expressing antigen 85A (MVA85A) boost strategy. MVA85A is now in clinical trials in the UK and Africa and the design of these trials, including the ethical and regulatory issues are discussed.</abstract><doi>10.1016/j.tube.2004.09.015</doi></addata></record>
fulltext fulltext
identifier ISSN: 1472-9792
ispartof Tuberculosis (Edinburgh, Scotland), 2005-03, Vol.85 (1-2), p.47-52
issn 1472-9792
language eng
recordid cdi_proquest_miscellaneous_17351798
source ScienceDirect Journals
title Boosting BCG with MV A85A: the first candidate subunit vaccine for tuberculosis in clinical trials
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T21%3A42%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Boosting%20BCG%20with%20MV%20A85A:%20the%20first%20candidate%20subunit%20vaccine%20for%20tuberculosis%20in%20clinical%20trials&rft.jtitle=Tuberculosis%20(Edinburgh,%20Scotland)&rft.au=McShane,%20H&rft.date=2005-03-01&rft.volume=85&rft.issue=1-2&rft.spage=47&rft.epage=52&rft.pages=47-52&rft.issn=1472-9792&rft_id=info:doi/10.1016/j.tube.2004.09.015&rft_dat=%3Cproquest%3E17351798%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_miscellaneous_173517983%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=17351798&rft_id=info:pmid/&rfr_iscdi=true